To elucidate the mechanisms underlying ALYREF-mediated cisplatin resistance in ovarian cancer, we conducted RNA-Seq in shALYREF and shNC A2780/DDP cells, along with m5C-BIS-Seq in A2780/DDP and parental cells. Here, ALYREF is linked to ovarian carcinoma.